MAR 15, 2018 6:52 PM PDT

Light controls variants of active ingredient in cannabis

WRITTEN BY: Invisiverse

Chemists have synthesized several variants of THC, the active ingredient in cannabis. The ability to alter its structure with light has led to a new tool for more effectively studying the body’s own cannabinoid system.

When many people hear the abbreviation THC (tetrahydrocannabinol), they immediately think of smoking marijuana and intoxication. But the substance is also of interest to medicine—when given to people suffering from serious illnesses, it relieves muscle cramps, pain, loss of appetite, and nausea.

THC works by binding to the corresponding cannabinoid-1 (CB1) receptors, which are located in the cell membrane and are present in large numbers in the central and peripheral nervous system. CB1 receptors play a major role in memory, motor coordination, mood, and cognitive processes.

When a THC molecule binds to one of these CB1 receptors, it changes form, triggering a cascade of various signals inside the cell. However, it is still hard to study CB1 receptors and their manifold functions, because cannabinoids such as THC are highly lipophilic, so they frequently embed themselves in the membranes made of fat molecules in an uncontrolled way.

To be able to use THC or variants of it more precisely for pharmaceutical and medical applications, it is important to gain a better understanding of CB1 receptors.

THC ‘antenna’

To study the diverse interactions between CB1 receptors and cannabinoids, ETH Zurich professor Erick Carreira and colleagues synthesized THC molecules and report the work in the Journal of the American Chemical Society.

The chemists synthesized four variants, or derivatives, of THC by attaching a light-sensitive “antenna” to the THC molecule. This antenna makes it possible to use light of a specific wavelength to precisely manipulate the altered molecule. Ultraviolet light changes the spatial structure of the antenna, and this change can be reversed again with blue light.

The researchers tested two of these derivatives in a living cell culture. The derivatives docked with CB1 receptors in the same way as naturally occurring THC. When the researchers irradiated the THC derivative with ultraviolet light, its structure altered just as the researchers expected, consequently activating the CB1 receptor. This triggers reactions such as the opening of the potassium ion channels located in the cell membrane, which causes potassium ions to flow out of the cell. The researchers were able to measure this with an electrode inserted into the cell.

When irradiated with blue light, the THC derivative returned to its original form, disabling the CB1 receptor as a result. The ion channels closed and the flow of potassium stopped. The researchers were able to activate and deactivate these processes using the corresponding colored pulses of light.

“This work is our successful proof of principle: light-sensitive THC variants are a suitable tool for controlling and influencing CB1 receptors,” says Michael Schafroth, a doctoral student with Carreira and a major contributor to the study.

Drug development

Additional projects using the findings are in progress: for example, another doctoral student in Carreira’s group, Roman Sarott, is working on synthesizing additional THC derivatives that react to long-wavelength red light. “Red light penetrates deeper into tissue than blue light,” says Sarott. “If we want to study CB1 receptors in a living organism, we need molecules that are sensitive to red light.”

Many cultures have long known of the intoxicating and therapeutic effect of THC. The identification of THC eventually led to the discovery of the endocannabinoid system, which involves the body’s native as well as exogenous substances in the cannabinoids class as well as their receptors in the body.

The pharmaceutical industry is also interested in gaining a better understanding of the endocannabinoid system so that it can better use specific components for pharmaceutical purposes. The system is considered a possible starting point for treatments for addiction, obesity, depression, and even Alzheimer’s and Parkinson’s.

 

This article was originally posted on futurity.org

About the Author
You May Also Like
AUG 22, 2020
Cannabis Sciences
People with Depression Twice as Likely to Use Cannabis
AUG 22, 2020
People with Depression Twice as Likely to Use Cannabis
Researchers from Columbia University have found that people with depression are around twice as likely to use cannabis t ...
SEP 10, 2020
Cannabis Sciences
Legalizing Cannabis Does Not Lead to Teenage Substance Abuse
SEP 10, 2020
Legalizing Cannabis Does Not Lead to Teenage Substance Abuse
Some say that decriminalizing cannabis may lead to an uptick in young people abusing the substance. Countering this fear ...
SEP 25, 2020
Health & Medicine
Does Cannabis Affect Brain Health in Older People?
SEP 25, 2020
Does Cannabis Affect Brain Health in Older People?
Demographic data shows rising cannabis use among older people, so what is the likely effect on cognitive funct ...
OCT 15, 2020
Cannabis Sciences
Can Cannabis Treat Traumatic Brain Injury?
OCT 15, 2020
Can Cannabis Treat Traumatic Brain Injury?
Traumatic brain injury (TBI) happens when the head is violently hit by an object or when an object pierces the skull and ...
NOV 19, 2020
Health & Medicine
Two Studies Raise Cannabis Heart Concerns
NOV 19, 2020
Two Studies Raise Cannabis Heart Concerns
Cannabis was under discussion at the American Heart Association’s Scientific Sessions 2020 (held November 13&ndash ...
DEC 07, 2020
Cancer
Can Cannabidiol inhibit head and neck cancer growth?
DEC 07, 2020
Can Cannabidiol inhibit head and neck cancer growth?
The usefulness of marijuana against cancer has been in question for some years now. Some are saying it has the potential ...
Loading Comments...